{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:22:21Z","timestamp":1791332541407,"version":"4.3.1"},"reference-count":41,"publisher":"FapUNIFESP (SciELO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>The clinical manifestations of lipodystrophy syndromes (LS) are hypoleptinemia, hyperglycemia, insulin resistance, dyslipidemia and hepatic steatosis. Leptin replacement therapy (LRT) is effective at improving these pathologies. Currently, there are no data compiling the evidence from the literature, and demonstrating the effect of LRT in LS patients. A systematic review of the MEDLINE and Cochrane Library databases was conducted to identify studies assessing the effect of LRT on metabolic and hepatic endpoints in patients with LS not associated with highly active antiretroviral therapy (HAART) use. Standardized mean differences (SMD) and 95% confidence intervals of pooled results were calculated for overall changes in glucose homeostasis, lipid profile, and hepatic physiology, using an inverse-variance random-effects model. After screening, 12 studies were included for review. Meta-analysis of results from 226 patients showed that LRT decreased fasting glucose [0.75 SMD units (range 0.36\u20101.13), p=0.0001], HbA1c [0.49 (0.17\u20100.81), p=0.003], triglycerides [1.00 (0.69\u20101.31), p&lt;0.00001], total cholesterol [0.62 (0.21\u20101.02), p=0.003], liver volume [1.06 (0.51\u20101.61), p=0.0002] and AST [0.41 (0.10\u20100.73) p=0.01]. In patients with non-HAART LS, LRT improves the outcome of several metabolic and hepatic parameters. Studies were limited by small populations and therefore large prospective trials are needed to validate these findings.<\/jats:p>","DOI":"10.1590\/0004-2730000003174","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T13:25:46Z","timestamp":1417267546000},"page":"783-797","source":"Crossref","is-referenced-by-count":15,"title":["Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints"],"prefix":"10.1590","volume":"58","author":[{"given":"Alexander J.","family":"Rodr\u00edguez","sequence":"first","affiliation":[{"name":"The Australian National University,  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Neeman","sequence":"additional","affiliation":[{"name":"The Australian National University,  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron G.","family":"Giles","sequence":"additional","affiliation":[{"name":"The Australian National University,  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Mastronardi","sequence":"additional","affiliation":[{"name":"The Australian National University,  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Paz Filho","sequence":"additional","affiliation":[{"name":"The Australian National University,  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: pathophysiology and advances in treatment","volume":"7","author":"Fiorenza CG","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1043-2760(00)00301-5","article-title":"Adipose tissue as an endocrine organ","volume":"11","author":"Ahima RS","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"ref3","first-page":"927","article-title":"Adipose tissue: a brief historical perspective and the present moment","volume":"52","author":"Lima FB","year":"2008","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref4","first-page":"583","article-title":"Biochemical, hormonal and genetic evaluation of the families of two Brazilian patients with type 2 familial partial lipodystrophy","volume":"57","author":"Caldas D","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1590\/S0004-27302010000800005","article-title":"Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy","volume":"54","author":"Paz G","year":"2010","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1590\/S0004-27302012000900001","article-title":"Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications","volume":"56","author":"Paz G","year":"2012","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan JL","year":"2010","journal-title":"Endocr Pract"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura I","year":"1999","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha V","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI200419511","article-title":"Site and mechanism of leptin action in a rodent form of congenital lipodystrophy","volume":"113","author":"Asilmaz E","year":"2004","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-7-8","article-title":"Effect of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice","volume":"7","author":"Nagao K","year":"2008","journal-title":"Lipids Health Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1586\/17446651.2014.894877","article-title":"Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy","volume":"9","author":"Simha V","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40265-013-0074-7","article-title":"Metreleptin: first global approval","volume":"73","author":"Chou K","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan JL","year":"2011","journal-title":"Endocr Pract"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000341398","article-title":"Consequences of stopping and restarting leptin in an adolescent with lipodystrophy","volume":"78","author":"Kamran F","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","article-title":"Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety","volume":"97","author":"Simha V","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting PF","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina TB","year":"2006","journal-title":"Psychol Methods"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor ED","year":"2005","journal-title":"Diabetes"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral EA","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-3165","article-title":"Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy","volume":"120","author":"Beltrand J","year":"2007","journal-title":"Pediatrics"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1530\/EJE-09-1027","article-title":"Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin","volume":"162","author":"Beltrand J","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong AY","year":"2010","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara K","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor ED","year":"2005","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran SA","year":"2004","journal-title":"Metabolism"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral EA","year":"2002","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park JY","year":"2007","journal-title":"Metabolism"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen KF","year":"2002","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh E","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"ref32","first-page":"194","article-title":"Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain","volume":"61","author":"Boguszewski CL","year":"2010","journal-title":"Endokrynol Pol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"E567","DOI":"10.1152\/ajpendo.00315.2011","article-title":"Leptin in human physiology and pathophysiology","volume":"301","author":"Mantzoros CS","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1111\/j.1467-789X.2010.00840.x","article-title":"Ten years of leptin replacement therapy","volume":"12","author":"Paz G","year":"2011","journal-title":"Obes Rev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/er.2012-1053","article-title":"Leptin\u2019s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals","volume":"34","author":"Moon HS","year":"2013","journal-title":"Endocr Rev"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000348541","article-title":"Rapid improvement of hepatic steatosis after initiation of leptin substitution in a leptin-deficient girl","volume":"79","author":"von Schnurbein J","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1530\/JME-13-0072","article-title":"Molecular pathways involved in the improvement of nonalcoholic fatty liver disease","volume":"51","author":"Paz G","year":"2013","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1111\/ajt.12436","article-title":"Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis","volume":"13","author":"Casey SP","year":"2013","journal-title":"Am J Transplant"},{"key":"ref39","series-title":"Briefing Document","year":"2013"},{"issue":"16","key":"ref40","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1073\/pnas.1015674108","article-title":"Leptin is an effective treatment for hypothalamic amenorrhea","volume":"108","author":"Chou SH","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","article-title":"The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients","volume":"54","author":"Musso C","year":"2005","journal-title":"Metabolism"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v58n8\/0004-2730-abem-58-8-0783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T18:55:12Z","timestamp":1495911312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302014000800783&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0004-27302014000800783"],"URL":"https:\/\/doi.org\/10.1590\/0004-2730000003174","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}